Dry Powder For oral Suspension
|more than 900 million units/annum
more than 300 million units/annum
more than 12 million bottles/annum
more than 7.5 million tubes/annum
more than 7.5 million bottles/annum
As a responsible corporation, Oman
Pharmaceutical Products firmly believes that maintaining
ecological balance is as important as business achievements and
that success is not acceptable at the cost of disturbing the
plant is landscaped with trees and green lawns to provide maximum
safety and environmental protection to the personnel as well as to
the surrounding environment. The emissions and effluents are
treated in elaborately designed filters and effluent treatment
plants as per local and international guidelines.
precision control measures, the plant aims to achieve zero
emission levels and also to neutralize waste through proper
treatment and disposal methods, thereby ensuring a clean, green
and safe environment.
insight into our plans:
The plant has
already received the approval from the MOH (Ministry of
Health) to go ahead with its R&D and QC departments.
tie-ups with IPL, Switzerland and Elder Pharmaceuticals
OPP has three
dedicated sections for hormones, antibiotics and general
continuing its research in the study of ‘lifestyle diseases’
and will be concentrating on chronic medication for CVS,
Diabetes, GIT and pain management.
OPP has a
production capacity to manufacture 900 mio tablets, 300 mio
caps, 19.5 mio bottles and 7.5 mio ointment tubes in one
single shift. This capacity can be raised by two to three
times as per requirements.
GCC pharmaceutical market is estimated at about USD 2 billion
and OPP is aiming to capture a slice of this market.
OPP is an
ultra modern pharmaceutical plant designed to conform to the
latest USFDA, UKMCA and EU standards. The thought process from
the conceptualization stage was to be a global pharmaceutical
placed a lot of emphasis on Quality Control, and has taken all
possible steps to ensure that its products strictly match
world regulatory standards. With this aim, we have invested
heavily in the latest QC equipments like computerized HPLC’s,
GC’s, UV Spectrophotometers.
plant has enough scope for expansion and there is adequate
space to put up another similar plant. In the first phase of
our operations, we are targeting the GCC and neighboring
countries, moving onto Africa subsequently. The second phase
will cover the EU and highly regulated markets like Australia,
NZ and South Africa. In the third phase, we plan to enter the
US markets. Throughout all phases, we will be entering and
consolidating smaller markets in Asia and Latin America.